

# Osteosarcoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/O3D52DF3E5DEN.html>

Date: July 2021

Pages: 100

Price: US\$ 2,000.00 (Single User License)

ID: O3D52DF3E5DEN

## Abstracts

This report can be delivered to the clients within 72 hours

DelveInsight's, "Osteosarcoma - Pipeline Insight, 2021," report provides comprehensive insights about 38+ companies and 38+ pipeline drugs in Osteosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Osteosarcoma Understanding

#### Osteosarcoma: Overview

Osteosarcoma, also called osteogenic sarcoma, is a kind of bone cancer. Most tumors develop in the bones around the knee, either in the lower part of the thigh bone (distal femur) or the upper part of the shinbone (proximal tibia). Osteosarcoma is the most common type of bone cancer, and accounts for about 3% of cancers that happen in children. The cause is not known. In some cases, osteosarcoma runs in families. At least one gene has been linked to an increased risk. The upper arm bone close to the shoulder (proximal humerus) is the next most common site. Osteosarcoma tumors can be categorized as low-grade, intermediate-grade, or high-grade. Pain is the most common symptom of osteosarcoma. This pain may come and go at first but, gradually, it becomes constant. Diagnosis of osteosarcoma is based on medical history and

physical examination; imaging tests like X-rays, CT scans, MRIs, bone scans, and PET scans; and biopsy. Treatment usually involves chemotherapy, surgery and, sometimes, radiation therapy.

'Osteosarcoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Osteosarcoma pipeline landscape is provided which includes the disease overview and Osteosarcoma treatment guidelines. The assessment part of the report embraces, in depth Osteosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Osteosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Osteosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Osteosarcoma.

## Osteosarcoma Emerging Drugs Chapters

This segment of the Osteosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Osteosarcoma Emerging Drugs

### Pamufetinib: Taiho Pharmaceutical

Pamufetinib (formerly TAS 115) is an orally administered, ATP-competitive, small molecule based dual MET/VEGFR2 (KDR) receptor tyrosine kinase inhibitor. The drug is in Phase III clinical studies for the treatment of osteosarcoma and in Phase II clinical studies to treat idiopathic pulmonary fibrosis and prostate cancer.

## Nivatrotamab: Y-mAbs Therapeutics

Nivatrotamab is a fully humanised bispecific antibody targeting both GD 2 and CD 3 receptors. The drug is in Phase II clinical studies for the treatment of neuroblastoma, osteosarcoma, and solid tumors.

Further product details are provided in the report.....

## Osteosarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Osteosarcoma drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players in Osteosarcoma

There are approx. 38+ key companies which are developing the therapies for Osteosarcoma. The companies which have their Osteosarcoma drug candidates in the most advanced stage, i.e. Phase III include, Taiho Pharmaceutical.

### Phases

DelveInsight's report covers around 38+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Osteosarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

**Osteosarcoma: Pipeline Development Activities**

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Osteosarcoma therapeutic drugs key

players involved in developing key drugs.

## Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Osteosarcoma drugs.

## Osteosarcoma Report Insights

Osteosarcoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Osteosarcoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Osteosarcoma drugs?

How many Osteosarcoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Osteosarcoma?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Osteosarcoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Osteosarcoma and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Taiho Pharmaceutical

Advanced BioDesign

Oncoinvent

Provectus Biopharmaceuticals

Nkarta Therapeutics

United Therapeutics

Guangzhou Xiangxue Pharmaceuticals

AlaMab Therapeutics

Y-mAbs Therapeutics

Jiangsu Hengrui Medicine

Exelixis

HLB

Chia Tai Tianqing Pharmaceutical Group

### Key Products

Pamufetinib

ABD 3001

OI-3

Rose Bengal sodium

NKX 101

Humanized dinutuximab

TAEST 16001

ALMB 0168

Nivatrotamab

Camrelizumab

Cabozantinib

Rivoceranib

Famitinib

TQ B3525

## Contents

Introduction

Executive Summary

Osteosarcoma: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Osteosarcoma – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Pamufetinib: Taiho Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Nivatrotamab: Y-mAbs Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

TAEST 16001: Guangzhou Xiangxue Pharmaceuticals

Product Description

Research and Development



Product Development Activities  
Drug profiles in the detailed report.....  
Preclinical/Discovery Stage Products  
    Comparative Analysis  
ABD 3001: Advanced BioDesign  
    Product Description  
    Research and Development  
    Product Development Activities  
Drug profiles in the detailed report.....  
Inactive Products  
    Comparative Analysis  
Osteosarcoma Key Companies  
Osteosarcoma Key Products  
Osteosarcoma- Unmet Needs  
Osteosarcoma- Market Drivers and Barriers  
Osteosarcoma- Future Perspectives and Conclusion  
Osteosarcoma Analyst Views  
Appendix

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Osteosarcoma
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Osteosarcoma
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Osteosarcoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/O3D52DF3E5DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O3D52DF3E5DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970